SOUTH PLAINFIELD, N.J., Dec. 5, 2023 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today an update on Translarna™ (ataluren) regulatory activities in Europe and the United States. As planned, PTC has submitted the briefing document as part of the re-examination of the…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.